REVIEW

Use of electroanalgesia and laser therapies as alternatives to opioids for acute and chronic pain management [version 1; peer review: 2 approved]

Paul F. White ¹⁻³, Ofelia Loani Elvir-Lazo ³, Lidia Galeas⁴, Xuezhao Cao^{3,5}

¹P.O. Box 548, Gualala, CA 95445, USA

²The White Mountain Institute, The Sea Ranch, CA, USA

³Department of Anesthesiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 95445, USA

⁴Orlando Family Medicine, Orlando, FL, USA

⁵First Hospital of China Medical University, Shenyang, China

V1 First published: 21 Dec 2017, 6(F1000 Faculty Rev):2161

<https://doi.org/10.12688/f1000research.12324.1>

Latest published: 21 Dec 2017, 6(F1000 Faculty Rev):2161

<https://doi.org/10.12688/f1000research.12324.1>

Abstract

The use of opioid analgesics for postoperative pain management has contributed to the global opioid epidemic. It was recently reported that prescription opioid analgesic use often continued after major joint replacement surgery even though patients were no longer experiencing joint pain. The use of epidural local analgesia for perioperative pain management was not found to be protective against persistent opioid use in a large cohort of opioid-naïve patients undergoing abdominal surgery. In a retrospective study involving over 390,000 outpatients more than 66 years of age who underwent minor ambulatory surgery procedures, patients receiving a prescription opioid analgesic within 7 days of discharge were 44% more likely to continue using opioids 1 year after surgery. In a review of 11 million patients undergoing elective surgery from 2002 to 2011, both opioid overdoses and opioid dependence were found to be increasing over time. Opioid-dependent surgical patients were more likely to experience postoperative pulmonary complications, require longer hospital stays, and increase costs to the health-care system. The Centers for Disease Control and Prevention emphasized the importance of finding alternatives to opioid medication for treating pain. In the new clinical practice guidelines for back pain, the authors endorsed the use of non-pharmacologic therapies. However, one of the more widely used non-pharmacologic treatments for chronic pain (namely radiofrequency ablation therapy) was recently reported to have no clinical benefit. Therefore, this clinical commentary will review evidence in the peer-reviewed literature supporting the use of electroanalgesia and laser therapies for treating acute pain, cervical (neck) pain, low back pain, persistent post-surgical pain after spine surgery ("failed back syndrome"), major joint replacements, and abdominal surgery as well as other common chronic pain syndromes

Open Peer Review

Approval Status

	1	2
version 1		
21 Dec 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Charles Argoff**, Albany Medical Center, Albany, USA

2. **Stephan A. Schug**, University of Western Australia, Perth, Australia

Any comments on the article can be found at the end of the article.

(for example, myofascial pain, peripheral neuropathic pain, fibromyalgia, degenerative joint disease/osteoarthritis, and migraine headaches).

Keywords

Non-pharmacologic analgesic techniques, Opioid abuse, Acute Pain, Chronic Pain, Electroanalgesia, Cold laser therapy

Corresponding author: Paul F. White (paul.white@cshs.org)

Author roles: **White PF:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Elvir-Lazo OL:** Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; **Galeas L:** Writing – Original Draft Preparation, Writing – Review & Editing; **Cao X:** Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: PFW is a non-paid consultant of Phoenix Thera-Lase Systems. The other authors declare that they have no competing interests.

Grant information: This research did not receive any grant funding from agencies in the public, commercial, or not-for-profit sectors. PFW's academic work is supported in part by a stipend from Cedars-Sinai Medical Center in Los Angeles, CA, and the White Mountain Institute (a private not-for-profit foundation) in The Sea Ranch, CA.

Copyright: © 2017 White PF *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: White PF, Elvir-Lazo OL, Galeas L and Cao X. **Use of electroanalgesia and laser therapies as alternatives to opioids for acute and chronic pain management [version 1; peer review: 2 approved]** F1000Research 2017, 6(F1000 Faculty Rev):2161 <https://doi.org/10.12688/f1000research.12324.1>

First published: 21 Dec 2017, 6(F1000 Faculty Rev):2161 <https://doi.org/10.12688/f1000research.12324.1>

Introduction

Pain is a common cause of disability and is extremely costly to society at large. The excessive reliance on opioid analgesics for treating both acute and chronic pain has contributed to the current global opioid epidemic. Recently, the Centers for Disease Control and Prevention (CDCP) reported that patients initially given a 1-day supply of opioid medication after surgery had a 6% likelihood of still using the drug a year later. However, that number rose to roughly 10% for patients given a 2-day supply and 45% for patients given a 40-day prescription. In light of the growing opioid crisis, we have emphasized the importance of using non-opioid analgesic drugs and techniques for acute and chronic pain management¹⁻³.

In 2007, a review article by international experts in pain management encouraged the more widespread use of opioid-containing analgesics for treating chronic pain by suggesting that “if only we (namely, physicians and nurses) could overcome our ‘opiophobia’, we would improve pain management”⁴. In an accompanying editorial¹, we argued that “less may be more” with respect to the use of opioid (narcotic) analgesics for acute (and chronic) pain therapy. Currently, 5–8 million people in the USA use opioids for chronic pain management⁵. It has become increasingly apparent that prolonged opioid use is a growing problem in previously opioid-naïve patients who receive narcotics for acute pain after a surgical procedure. Excessive reliance on opioid analgesics for postoperative pain control can lead to prolonged opioid dependence after both major⁶ and minor⁷ surgery. In a large retrospective study involving over 390,000 older outpatients undergoing minor ambulatory surgery procedures⁷, older patients receiving prescription opioid analgesics within 7 days of discharge were 44% more likely to continue using opioids 1 year after surgery. More recently, Goesling *et al.*⁶ reported that for many patients taking opioid analgesics before major joint replacement surgery, as well as opioid-naïve patients undergoing arthroplasty procedures, opioid use persisted after surgery despite the absence of joint-related pain. More recently, Cauley *et al.*⁸ reported on a large cohort of opioid-naïve patients undergoing abdominal surgery who continued to use opioid analgesics 3–6 months after surgery. Moreover, adjunctive use of epidural local analgesia was not protective against persistent opioid use in this opioid-naïve population⁹. Although opioid-related side effects (for example, nausea, vomiting, constipation, ileus, bladder dysfunction, pruritus, sedation, visual hallucinations, and ventilatory depression) are well known, there are growing concerns regarding long-term physical dependence and addiction liability with continued opioid use after surgical procedures.

Prolonged use of opioid analgesics is associated with an increased risk of more serious complications, including opioid use disorder, overdose, and death¹⁰. Interestingly, no study of prolonged opioid use has ever demonstrated long-term benefits for the users. An epidemiological study by Eriksen *et al.*¹¹ involving patients with chronic pain treated with opioids for 5 years provided compelling evidence that opioids were not a panacea for chronic pain. In fact, the patients’ quality of life failed to improve despite escalating doses of opioids over the 5-year study period. The authors concluded that “it is remarkable that opioid treatment of

long-term/chronic non-cancer pain does not seem to fulfil any of the key outcome treatment goals, namely pain relief, improved quality of life and improved functional capacity”¹¹. More recent studies suggest that long-term opioid use can actually retard functional recovery. In a 2012 commentary, Sullivan and Ballantyne¹² asked the rhetorical question, “what are we treating with long-term opioid therapy?” As the opioid epidemic continues to spread and deaths due to opioid overdoses increase, it is clear that the only “winners” are the pharmaceutical drug manufacturers.

A 2016 article in *Time* magazine described a new paradigm for treating opioid addiction¹³. Predictably, the solution being offered by the pharmaceutical industry involves giving more drugs! The “new” drug touted as the solution to opioid dependency (Suboxone) is a combination of two old drugs, namely buprenorphine (a weak partial opioid agonist) and naloxone (an opioid antagonist). A more recent article¹⁴ describes the cost of the “follow on” drugs used to counteract opioid-related side effects (for example, nausea, constipation, and reduced testosterone levels) and overdoses. In 2016, US pharmaceutical companies had sales of \$8.6 billion on 336 million opioid prescriptions. The “follow on” drug market is currently valued at more than \$3 billion per year, and sales of drugs used to counteract opioid-induced constipation exceed \$2 billion per year¹⁴. It is time to seriously consider the use of “alternative” non-pharmacologic therapies for treating chronic pain rather than simply giving more opioid compounds and hoping for a different result⁵.

Given the fact that the long-term use of opioid analgesics fails to improve the lives of patients suffering from chronic pain and costs the health-care system billions of dollars to treat opioid overdoses, it is somewhat surprising that the health-care practitioners (and third-party payers) have been reluctant to seriously consider the use of non-pharmacologic “alternative” therapies for managing pain. The use of non-pharmacologic modalities has been questioned by medical practitioners because of the perceived lack of prospective, randomized, double-blind sham-controlled studies supporting their use in clinical practice. Although this skepticism may be warranted for some so-called alternative pain therapies, there are in fact many well-controlled studies confirming the benefits of using electroanalgesia and laser therapy for improving acute and chronic pain management. Nevertheless, these non-pharmacologic analgesic modalities remain grossly under-utilized in clinical practice. In a 2006 clinical commentary regarding a study involving the use of complementary alternative therapies for reducing postoperative pain after open heart surgery¹⁵, Oz and Olivo¹⁶ suggested that it was time to consider incorporating complementary and alternative medical practices into conventional medical treatments. Other studies have suggested that perioperative imagery, massage, and music can reduce pain and anxiety after surgery^{17,18}. A 2007 editorial on the potentially beneficial role of “alternative” therapies as part of a multimodal approach for reducing anxiety, pain, and emetic symptoms in the perioperative period¹⁹ suggested that it was time for practitioners to “get on board” by incorporating non-traditional medical therapies into their everyday clinical practices. Sadly, 10 years later in the face of an opioid epidemic, the emphasis of the medical

community remains on pharmacotherapy. In this F1000 Faculty Review, we discuss clinical studies describing the benefits of using electroanalgesia and laser therapy as adjuvants in the management of acute and chronic pain.

Electroanalgesia

Electroanalgesia is a form of neuromodulation therapy which encompasses electro-acupuncture (EA), ultrasound-guided acupotomy, percutaneous electrical nerve stimulation (PENS), transcutaneous electrical nerve stimulation (TENS), and peripheral nerve stimulation (PNS). Patients who experience significant improvement in pain and disability with PNS may be candidates for implantation of a spinal cord stimulator^{20,21}. However, the risk of mechanical failure, infection, and neurologic complications, as well as the high costs, are strong deterrents to using this highly invasive electro-analgesic technique. The less invasive forms of electroanalgesia (for example, TENS, EA, PENS, and PNS) have been reported to produce significant short-term reductions in the levels of acute and chronic pain and should be used prior to even considering the use of an implantable device.

Gan *et al.*²² reported that TENS applied at acupoints reduced both postoperative pain and emesis, confirming earlier studies^{23–27}. TENS also reduced pain and improved patient satisfaction during minor office procedures²⁸. However, in a comparison of TENS and parasternal local anesthetic blocks for pain management after cardiac surgery²⁹, the local anesthetic-based technique was found to be significantly more efficacious. TENS produced modest short-term reductions in pain and improvements in physical activity in patients experiencing a variety of chronic pain syndromes (for example, low back pain^{30–35}, neck pain³⁶, osteoarthritis/gonarthrosis^{37,38}, abdominal/pelvic pain³⁹, myofascial pain syndrome⁴⁰, and temporal-mandibular disorders⁴¹). However, a recent review of electrotherapy modalities for treating chronic rotator cuff diseases⁴² concluded that, in contrast to more invasive electroanalgesia modalities (for example, EA), TENS was not consistently superior to placebo treatments. In patients undergoing total knee arthroplasty procedures, TENS offered no significant advantage with respect to improving pain control and functional recovery compared with placebo treatments⁴³. Finally, Salazar *et al.*⁴⁴ recently reported that there was only low-quality evidence supporting the effectiveness of TENS for pain relief in patients with fibromyalgia. However, these investigators found moderate-quality evidence for the effectiveness of EA in treating fibromyalgia-related pain⁴⁴. Thus, the current evidence suggests that TENS techniques are significantly less effective than electroanalgesia techniques such as EA and PENS, which involve the insertion of multiple acupuncture-like needles⁴⁵.

Sator-Katzenschlager *et al.*³¹ and others³² have reported on the short- and long-term benefits of EA in patients with chronic low back pain. In a recent study involving elderly patients undergoing spine surgery, Zhang *et al.*⁴⁶ found that preoperative EA (versus “sham” treatments) reduced both intraoperative anesthetic and analgesic requirements, levels of inflammatory mediators, and residual postoperative cognitive dysfunction in elderly surgical patients. These EA studies are consistent with

studies involving the use of PENS in patients with chronic low back pain⁴⁷ and sciatica³³. Moreover, PENS was found to be significantly more effective than TENS and exercise therapy^{33,47}. In a recent comparative study, PENS was found to be more effective than “dry needling” in improving pain control in patients with myofascial chronic neck pain⁴⁸. A growing body of literature supports the short-term benefits of EA and PENS techniques when administered as an adjuvant to conventional medical approaches in the management of a wide variety of acute and chronic pain syndromes, including post-surgical pain, low back pain, sciatica, neck pain, knee osteoarthritis, headaches, peripheral neuropathic pain, and fibromyalgia^{33,44,47–52}. In a recent comparative study, EA was also found to be more effective in facilitating functional recovery in patients with knee osteoarthritis than the potent non-steroidal anti-inflammatory drug meloxicam⁵³. Interestingly, acupotomy EA was reported to be superior to conventional EA in patients with knee osteoarthritis with respect to pain control and functional recovery⁵⁴. Despite numerous controlled studies in the peer-reviewed literature supporting their clinical efficacy (Table 1), minimally invasive electroanalgesia techniques have failed to gain widespread clinical acceptance because they are time-consuming to perform and insurance reimbursement is extremely low compared with other medical procedures. Although there is some ‘cumulative’ benefit after a series of electroanalgesia treatments, maintenance therapy is typically required because the duration of pain relief after each treatment session is fairly short-lived (<48 hours).

Laser therapy

Compared with electroanalgesia and exercise therapy, laser therapy is a relatively recent development in medicine. The first cold laser was US Food and Drug Administration (FDA)-approved for treating pain in 2001, and low-level laser therapy (LLLT), also known as cold laser therapy, has been used in the USA since only 2002. High-intensity laser therapy (HILT), also known as laser heat therapy, is an even more recent development; initial publications appeared in 2011. Laser therapy involves a simple, non-invasive, “point-and-shoot” technique which can be performed by technicians. Cellular chromophores are presumed to be the receptor sites responsible for the beneficial effects of the laser light beam, including both cytochrome c oxidase (with absorption peaks in the near-infrared range) and photoactive porphyrins⁵⁵. Mitochondria are also thought to be a site for the therapeutic effects of infrared light, leading to increased ATP production, modulation of reactive oxygen species, and induction of transcription factors. These effects lead to increased cell proliferation and migration by fibroblasts; reduction in the levels of cytokines, growth factors, and inflammatory mediators; and increased tissue oxygenation, leading to enhanced control of the inflammatory process, reduced pain, and improved wound healing^{56–59}. Studies with laser therapy have confirmed enhanced wound healing in both diabetic⁶⁰ and non-diabetic^{59,61,62} patients. Applying LLLT within the first 5 days of herpes zoster eruption also significantly reduced the incidence of post-herpetic neuralgia⁶³.

Many sham-controlled studies have reported that LLLT is effective in alleviating acute pain associated with a variety of superficial medical and surgical conditions (for example, oral

Table 1. Comparison of typical characteristics and applications of transcutaneous and percutaneous electroanalgesia techniques for treating acute and chronic pain.

	Transcutaneous electroanalgesia techniques	Percutaneous electroanalgesia techniques
Examples	Transcutaneous electrical nerve stimulation (TENS) Acupoint-like transcutaneous electrical nerve stimulation	Electroacupuncture (EA) Percutaneous electrical nerve stimulation (PENS) Peripheral nerve stimulation
Application	Non-invasive Cutaneous pads (disposable)	Minimally invasive Acupuncture needles inserted through skin
Duration of pain relief	Limited short-term benefits (<24 hours)	Short-term and some longer-term benefits (24–72 hours)
Cost	Low (self-administered)	High (personnel required)
Time required to perform techniques	Minimal	More labor-intensive and time-consuming to perform
Applications for acute and chronic pain management	Acute postoperative pain, low back pain, neck pain, osteoarthritis/gonarthrosis, abdominal/pelvic pain, myofascial pain syndrome, chronic rotator cuff diseases, and temporomandibular disorders	Acute post-surgical pain, low back pain, sciatica, neck pain, knee osteoarthritis, osteoarthritis/gonarthrosis, headaches, peripheral neuropathic pain, and fibromyalgia

surgery^{64–66}, nipple pain associated with prolonged breastfeeding⁶⁷, plantar fasciitis^{68,69}, and carpal tunnel syndrome⁷⁰). In women with chronic myofascial pain, LLLT reduced the pain intensity⁷¹. Interestingly, LLLT has been reported to reduce acute pain after coronary artery bypass graft surgery^{72,73}. Recent studies also reported that LLLT could improve sensory function in patients with peripheral somatosensory neuropathy and neuropathic pain^{74,75}. However, other investigators have reported sham-controlled studies with negative results using LLLT in patients with superficial medical conditions (for example, plantar fasciitis)⁷⁶. Despite early clinical studies reporting benefits from LLLT in patients with fibromyalgia^{77,78}, a recent study by Vayvay *et al.*⁷⁹ reported that LLLT was not significantly better than sham treatments and Kinesio Tape.

Several studies have described the use of LLLT for treating dental pain after oral surgery, with reduced orthodontic pain at 6 hours, 24 hours, 3 days, and even 1 week after surgery⁸⁰. Alan *et al.*⁸¹ reported that although LLLT reduced trismus and swelling after oral surgery, pain was only decreased on the 7th postoperative day. More recently, LLLT administered after maxillofacial surgery was reported to accelerate healing and enhance quality of life related to oral health⁸². However, Chen *et al.*⁸³ reported that LLLT had limited efficacy in reducing pain in patients with temporal-mandibular joint disorders. Although LLLT is reported to be more effective than “traditional procedures” in the management of oro-facial pain, it remains to be determined which power level and wavelength produce the optimal outcomes⁸⁴.

LLLT has been reported to be a useful adjunct treatment for oral mucositis in patients with cancer^{85–90}. However, in patients with breast cancer and unilateral lymphedema, LLLT failed to significantly improve their quality of life, pain scores, grip strength, or limb volume⁹¹. In contrast, long-term beneficial effects have been reported with pulsed HILT in the treatment of

post-mastectomy pain syndrome⁹². A recent literature review⁹³ suggested that LLLT might be a promising option for the management of cancer treatment-related side effects (for example, oral mucositis, radiodermatitis, lymphedema, and chemotherapy-induced peripheral neuropathic pain). Although LLLT has been reported to have a suppressive effect on cancer cells^{94–97}, studies using rodent models suggest that it might modify cancer cell behavior and actually lead to stimulation of dysplastic cells^{98–101}. For example, Rhee *et al.*¹⁰² reported that LLLT increased tumor size in rodents when thyroid cancer cells were directly exposed to photodynamic (laser) therapy. Clearly, additional studies with both LLLT and HILT are needed in patients with cancer.

In a sham-controlled, prospective safety and efficacy study of LLLT in patients with subacute musculoskeletal back pain, Basford *et al.*¹⁰³ concluded that LLLT produced a “moderate” reduction in pain while improving the patients’ perception of clinical benefit and level of functionality. Glazov *et al.*¹⁰⁴ found evidence to support a short-term benefit of LLLT in treating low back pain in patients with a shorter duration of pain symptoms. However, these investigators suggested that greater pain-relieving benefits were achieved when higher laser dosages were administered (that is, HILT versus LLLT). This speculation was confirmed by Boyraz *et al.*¹⁰⁵ and Chen *et al.*¹⁰⁶, who reported that HILT in combination with exercise produced significant functional improvements with longer-lasting beneficial effects than exercise therapy alone in patients with lumbar disc herniation. HILT also appeared to be an effective alternative to spine surgery for reducing pain and improving the performance of activities of daily living in patients with chronic back pain¹⁰⁷.

In a recent review⁴², the authors stated that LLLT has only short-term benefits (versus sham) in treating rotator cuff disease; however, HILT was effective in minimizing pain and disability

and increasing range of motion in patients with shoulder pain¹⁰⁸. Similarly, in a 2013 systematic review of LLLT in treating chronic neck pain, the authors reported that although the benefits observed were statistically significant, the differences failed to achieve a “minimally-important clinical difference”¹⁰⁹. In contrast, Alayat *et al.* found that HILT combined with exercise in patients with chronic low back¹¹⁰ and neck¹¹¹ pain was more effective than exercise therapy alone and also had a more sustained effect in decreasing pain and functional disability (for example, improving range of motion), and beneficial effects lasted for up to 3 months. Chow *et al.*¹¹² reported that laser therapy reduced pain immediately after treatment sessions in patients with acute neck pain and for up to 22 weeks after completion of a series of treatments in patients with chronic neck pain. Haładaj *et al.*¹¹³ demonstrated that HILT also produced clinically-significant analgesic efficacy in patients with cervical radicular pain syndrome and cervical spondylosis. Dundar *et al.*¹¹⁴ reported that HILT is an effective therapeutic method in the treatment of patients with myofascial pain syndrome of the trapezius muscle, a common cause of chronic neck pain.

Kim *et al.*¹¹⁵ and others¹¹⁶ reported that HILT was an effective non-surgical intervention for patients with knee osteoarthritis, reducing pain and improving their ability to perform activities of daily living. Alayat *et al.*¹¹⁷ reported that, in men with osteopenia and osteoporosis, HILT combined with exercise was more effective than exercise alone in reducing pain and improving

quality of life after a series of treatments. Kheshie *et al.*¹¹⁸ and others¹¹⁹ have reported that HILT is significantly more effective than LLLT in treating chronic osteoarthritis-related pain. These findings with HILT (versus LLLT) were also confirmed in a study by Alayat *et al.*¹²⁰ in patients with Bell’s palsy. HILT was also effective in the short-term management of pain and disability related to subacromial impingement syndrome, frozen shoulder and lateral epicondylitis^{121–123}. HILT at wavelengths of 830 and 1,064 nm was better than TENS in improving control of pain and paresthesias secondary to carpal tunnel syndrome¹²⁴. Analogous to LLLT, HILT has also been used to treat acute headache pain^{125–127}, degenerative joint conditions^{115–119,128–131}, neuropathic pain syndromes^{64,132–136}, and a wide variety of musculoskeletal disorders, including fibromyalgia^{77–79,114,137}.

A more powerful version of HILT has been introduced using class IV lasers producing more than 25 W of power (for example, the Phoenix Thera-Lase device) (Table 2). Huang *et al.*¹³⁸ demonstrated that the beneficial outcomes of laser therapy were directly related to the amount of energy (power) administered. The energy density (in joules per square centimeter) or power (in watts) appears to be strongly related to the efficiency of laser radiation in reducing pain and inflammation. Power density represents the laser/light-emitting diode incident power in watts on the tissue spot size (that is, output power divided by the size of the irradiated area in watts per square meter). The higher power density is responsible for regulating or “speeding up” the

Table 2. Comparison of primary characteristics of low-level laser therapy and high-intensity laser therapy devices for the management of common pain syndromes.

	Low-level laser therapy (LLLT)	High-intensity laser therapy (HILT)
Laser class	I, Im, II, III	IV
Wavelength	600–980 nm	660–1,275 nm
Power	<1 W	1–75 W
Penetration abilities	Low (<2 cm)	Deep (5–15 cm)
Temperature changes	<1.0°C	Low thermal accumulation
Applications for acute and chronic pain management	Superficial postoperative pain Osteoarthritis Low back pain Neck pain Plantar fasciitis Dental pain Mucositis-associated pain Acute and chronic pain related to herpes virus Trigeminal neuralgia Wound repair The pain of muscle injury Shoulder pain Carpal tunnel syndrome Fibromyalgia-related pain Headache Opioid dependency	Postoperative pain Osteoarthritis Hemophilic arthropathy Low back pain related to herpes virus Myofascial pain syndrome Shoulder pain Fibromyalgia-related pain Opioid dependency Note: Several of the applications listed for low-level laser therapy have not been studied using high-intensity laser therapy devices. However, there is no reason to expect that they would not respond as well or better.

transport of electrons in the mitochondrial respiratory chain⁹⁰. The World Association of Laser Therapy has established that target tissues need an energy density of 5–7 J/cm² or higher to elicit a clinically significant biological cellular response¹³⁹.

The more powerful HILT devices are also referred to as laser heat devices¹⁴⁰. In addition, some of these powerful laser devices function at longer wavelengths; for example, the Phoenix Thera-Lase (Phoenix Thera-Lase Systems, Dallas, TX, USA), which produces up to 75 W of power, operates at a wavelength of 1,275 nm. Therefore, the laser beam produced by these devices can penetrate more deeply into the soft tissue because of their enhanced power and the reduced absorption of the laser beam by melanin and hemoglobin (Figure 1)³. Profound and long-lasting analgesic effects have recently been reported with this HILT device in patients with chronic post-surgical pain requiring the use of opioid analgesics¹⁴¹, professional athletes with degenerative joint disease requiring non-opioid analgesics¹⁴², and a woman with long-standing drug-resistant fibromyalgia¹³⁷. The fibromyalgia case report suggests that the use of HILT at 42–75 W of power can produce more profound and longer-lasting beneficial effects than standard treatment protocols utilizing LLLT⁷⁹ and less powerful HILT devices¹⁴⁰. Importantly, LLLT studies have reported that photobiomodulation therapy produced greater improvement in muscular performance and accelerating recovery when it is administered prior to exercising^{143,144}. Although Foley *et al.*¹⁴⁵ reported that LLLT

facilitated a faster recovery of injured university athletes, they failed to include either a control or an active comparator group.

Larger-scale studies are clearly needed to verify the benefits of HILT compared with both LLLT and electroanalgesia in decreasing acute and chronic pain and improving long-term clinical outcomes. Finally, determining the optimal power and wavelength for each clinical condition is critically important in optimizing both LLLT and HILT. For example, de Oliveria *et al.*¹⁴⁴ compared 100, 200, and 400 mW of power and found that with LLLT a higher power does not necessarily produce a better result with respect to improvement in muscle performance. These authors also recommended using a wavelength of 810 nm for achieving optimal results with LLLT. However, Bordvik *et al.*¹⁴⁶ reported that a 910 nm wavelength produced greater tissue penetration than 810 nm with a super-pulsed laser.

Super-pulsed class IIIB lasers (for example, Multi Radiance, Medical [Solon, Ohio], and Thera-Lase [Toronto, Ontario, Canada]) can produce a peak power of up to 100 W without causing tissue warming in contrast to the more powerful class IV lasers (for example, LightForce lasers [LiteCure, Newark, DE] produces 0.5–25 W at wavelengths of 980/810 nm and Phoenix Thera-Lase [Phoenix Thera-Lase Systems, Dallas, TX] produces 1–75 W at a wavelength of 1,275 nm). In a sham-controlled study, Leal-Junior and colleagues¹⁴⁷ reported that a super-pulsed laser was effective in decreasing pain and improving the quality of

Figure 1. The absorption effect of different wavelengths of infrared light by water, hemoglobin, oxyhemoglobin, and melanin. This figure illustrates one of the effects of the wavelength differences between the Phoenix Thera-Lase and other commercially available high-intensity laser therapy devices (for example, LightForce/LiteCure, erbium-doped yttrium aluminium garnet laser [Er:YAG], and neodymium-doped YAG [Nd:YAG]) with respect to infrared light absorption. These spectra are available from online sources.

life in patients with non-specific knee pain. Of interest, a recent study by de Marchi *et al.*¹⁴⁸ reported that low-powered ‘pulsed’ lasers produced superior effects with respect to delayed-onset muscle soreness and elevations in creatine kinase activity than both low- and high-powered continuous lasers. Notarnicola *et al.*¹⁴⁹ reported that HILT with 5 W of power at wavelengths of 650 nm, 810 nm, and TRIAX (810/980/1,064 nm) reduces low back pain scores and disability at 1, 2, and 4 months post-treatment. The greatest efficacy in promoting nerve regeneration and modulating pain transmission was associated with the use of the longer wavelengths (810/980/1,064 nm versus 650 nm).

Discussion

In a recent “call to action” to end the opioid epidemic in this country¹⁵⁰, the US Surgeon General pointed out that the annual number of overdose deaths involving prescription opioids has nearly quadrupled since 2000 and this increase parallels the marked growth in the quantity of opioid pain relievers being prescribed¹⁵¹. Prescription opioid addiction and misuse have also contributed to a resurgence in heroin use and the spread of HIV and hepatitis C¹⁵². In the “Turn the Tide” Rx Pocket card which the government recently mailed to all practicing clinicians in this country, there was no mention of non-pharmacologic approaches to treating pain. However, in the recent FDA response to the opioid crisis, Califf *et al.*¹⁵³ emphasized that more “alternatives” to opioid analgesics are needed, including non-pharmacologic therapies. According to the FDA leadership, “non-pharmacologic approaches to pain treatment were identified as an urgent priority”¹⁵³. The new Clinical Guidelines Committee of the American College of Physicians also endorsed the use of non-invasive treatments such as laser therapy for the treatment of acute, subacute, and chronic low back pain¹⁵⁴. The CDCP has also recently emphasized the importance of finding non-pharmacologic alternatives to opioid analgesic medications for treating pain¹⁵⁵. These authors reported that patients initially given a 1-day supply of opioid medication had a 6% likelihood of still using the drug a year later. However, that number rose to roughly 10% for patients given a 2-day supply and to 45% for patients given a 40-day prescription.

Of importance, Barnett *et al.*¹⁵⁶, in a recent issue of the *New England Journal of Medicine*, reported that long-term opioid use was increased in previously opioid-naïve patients who received treatment in an emergency department from high (versus low) intensity opioid prescribers. Altering the prescribing habits of physicians and their surrogates will clearly help; however, in order to effectively deal with the current opioid crisis, more innovative non-pharmacologic approaches for treating acute and chronic pain are clearly needed¹⁵⁷. In this review, we have described numerous clinical studies published within the last 5 years which support the use of non-pharmacologic electro-analgesic and laser therapies for managing both acute and chronic pain.

Conclusions

The consequences of the widespread reliance on opioid-containing medication for managing acute and chronic pain should not be surprising. Many different electro-analgesic and laser therapy techniques have been described in the peer-reviewed

literature for treating acute and chronic pain. However, these “alternative” therapies have failed to achieve broad acceptance in the medical community because of lingering questions regarding their analgesic efficacy, a lack of long-term outcome studies, and low reimbursement by third-party payers to the health-care providers administering these non-traditional therapeutic modalities. Although the use of powerful HILT devices appears to produce more profound and sustained beneficial effects than electroanalgesia and LLLT in the treatment of acute and chronic pain, this therapeutic modality has also failed to achieve widespread acceptance in the medical community because of a lack of knowledge regarding the potential long-term benefits of HILT among health-care providers, low third-party reimbursement rates, and the high cost associated with purchasing these more powerful laser devices. The mechanism of action of both electroanalgesia and laser therapy appears to involve neuromodulation of peripheral nerves using low-level electrical currents¹⁵⁸ and infrared light^{159,160}, respectively. Acustimulation, a popular form of electroanalgesia, has been reported to trigger the release of neurotransmitters and endogenous opioid-like substances and to activate c-fos within the central nervous system (CNS). Laser photobiomodulation appears to induce direct inhibitory effects on peripheral nerves, which reduces acute pain input into the CNS. In chronic pain patients, laser-induced changes in the spinal cord produces longer-term suppression of pain in the CNS.

Given the current opioid crisis in the USA, it is time to seriously consider incorporating these “alternative” analgesic therapies into treatment protocols for managing acute and chronic pain rather than adding more “fuel to the fire” by administering even more opioid-related drugs (157). A simple, safe, and effective non-invasive pain therapy without side effects could significantly reduce the dependence on oral opioid-containing medications in the post-discharge period after surgery. These non-pharmacologic therapies would also be cost-effective alternatives to opioids for treating chronic pain not responding to non-opioid analgesic medications. It would appear that both electroanalgesia and laser therapy are safer and more cost-effective for managing chronic pain than the long-term use of opioid analgesics. Finally, HILT could prove to be a valuable therapy for treating patients who have become addicted to opioid-containing prescription medications.

Author contributions

Each co-author contributed to the preparation of the manuscript, including the creation of the tables.

Competing interests

PFW is a non-paid consultant of Phoenix Thera-Lase Systems. The other authors declare that they have no competing interests.

Grant information

This research did not receive any grant funding from agencies in the public, commercial, or not-for-profit sectors. PFW’s academic work is supported in part by a stipend from Cedars-Sinai Medical Center in Los Angeles, CA, and the White Mountain Institute (a private not-for-profit foundation) in The Sea Ranch, CA.

References

1. White PF, Kehlet H: **Improving pain management: are we jumping from the frying pan into the fire?** *Anesth Analg*. 2007; **105**(1): 10–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. White PF: **Multimodal analgesia: its role in preventing postoperative pain.** *Curr Opin Investig Drugs*. 2008; **9**(1): 76–82.
[PubMed Abstract](#)
3. White PF: **What are the advantages of non-opioid analgesic techniques in the management of acute and chronic pain?** *Expert Opin Pharmacother*. 2017; **18**(4): 329–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Brennan F, Carr DB, Cousins M: **Pain management: a fundamental human right.** *Anesth Analg*. 2007; **105**(1): 205–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
5. Reuben DB, Alvanzo AA, Ashikaga T, *et al.*: **National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain.** *Ann Intern Med*. 2015; **162**(4): 295–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Goesling J, Moser SE, Zaidi B, *et al.*: **Trends and predictors of opioid use after total knee and total hip arthroplasty.** *Pain*. 2016; **157**(6): 1259–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
7. Alam A, Gomes T, Zheng H, *et al.*: **Long-term analgesic use after low-risk surgery: a retrospective cohort study.** *Arch Intern Med*. 2012; **172**(5): 425–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
8. Cauley CE, Anderson G, Haynes AB, *et al.*: **Predictors of In-hospital Postoperative Opioid Overdose After Major Elective Operations: A Nationally Representative Cohort Study.** *Ann Surg*. 2017; **265**(4): 702–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Ladha KS, Patomo E, Liu J, *et al.*: **Impact of Perioperative Epidural Placement on Postdischarge Opioid Use in Patients Undergoing Abdominal Surgery.** *Anesthesiology*. 2016; **124**(2): 396–403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Olsen Y: **The CDC Guideline on Opioid Prescribing: Rising to the Challenge.** *JAMA*. 2016; **315**(15): 1577–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Eriksen J, Sjogren P, Bruera E, *et al.*: **Critical issues on opioids in chronic non-cancer pain: an epidemiological study.** *Pain*. 2006; **125**(1–2): 172–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Sullivan MD, Ballantyne JC: **What are we treating with long-term opioid therapy?** *Arch Intern Med*. 2012; **172**(5): 433–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Park A: **A new paradigm for opioid addiction: more drugs.** *TIME* magazine. 2016.
[Reference Source](#)
14. Edwards HS: **The Drug Cascade.** *TIME* magazine. 2017.
[Reference Source](#)
15. Kshetry VR, Carole LF, Henly SJ, *et al.*: **Complementary alternative medical therapies for heart surgery patients: feasibility, safety, and impact.** *Ann Thorac Surg*. 2006; **81**(1): 201–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Oz MC, Olivo EL: **Invited commentary.** *Ann Thorac Surg*. 2006; **81**(1): 205–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Tse MM, Chan MF, Benzie IF: **The effect of music therapy on postoperative pain, heart rate, systolic blood pressures and analgesic use following nasal surgery.** *J Pain Palliat Care Pharmacother*. 2005; **19**(3): 21–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Sendelbach SE, Halm MA, Doran KA, *et al.*: **Effects of music therapy on physiological and psychological outcomes for patients undergoing cardiac surgery.** *J Cardiovasc Nurs*. 2006; **21**(3): 194–200.
[PubMed Abstract](#)
19. White PF: **Use of alternative medical therapies in the perioperative period: is it time to get on board?** *Anesth Analg*. 2007; **104**(2): 251–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Deogaonkar M, Slavin KV: **Peripheral nerve/field stimulation for neuropathic pain.** *Neurosurg Clin N Am*. 2014; **25**(1): 1–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Chakravarthy K, Nava A, Christo PJ, *et al.*: **Review of Recent Advances in Peripheral Nerve Stimulation (PNS).** *Curr Pain Headache Rep*. 2016; **20**(11): 60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
22. Gan TJ, Jiao KR, Zenn M, *et al.*: **A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting.** *Anesth Analg*. 2004; **99**(4): 1070–5, table of contents.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Wang B, Tang J, White PF, *et al.*: **Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement.** *Anesth Analg*. 1997; **85**(2): 406–13.
[PubMed Abstract](#)
24. Chen L, Tang J, White PF, *et al.*: **The effect of location of transcutaneous electrical nerve stimulation on postoperative opioid analgesic requirement: acupoint versus nonacupoint stimulation.** *Anesth Analg*. 1998; **87**(5): 1129–34.
[PubMed Abstract](#)
25. Zárate E, Mingus M, White PF, *et al.*: **The use of transcutaneous acupoint electrical stimulation for preventing nausea and vomiting after laparoscopic surgery.** *Anesth Analg*. 2001; **92**(3): 629–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Hamza MA, White PF, Ahmed HE, *et al.*: **Effect of the frequency of transcutaneous electrical nerve stimulation on the postoperative opioid analgesic requirement and recovery profile.** *Anesthesiology*. 1999; **91**(5): 1232–8.
[PubMed Abstract](#)
27. White PF, Hamza MA, Recart A, *et al.*: **Optimal timing of acustimulation for antiemetic prophylaxis as an adjunct to ondansetron in patients undergoing plastic surgery.** *Anesth Analg*. 2005; **100**(2): 367–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Lisón JF, Amer-Cuenca JJ, Piquer-Martí S, *et al.*: **Transcutaneous Nerve Stimulation for Pain Relief During Office Hysteroscopy: A Randomized Controlled Trial.** *Obstet Gynecol*. 2017; **129**(2): 363–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Ozturk NK, Baki ED, Kavakli AS, *et al.*: **Comparison of Transcutaneous Electrical Nerve Stimulation and Parasternal Block for Postoperative Pain Management after Cardiac Surgery.** *Pain Res Manag*. 2016; **2016**: 4261949.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Gadsby JG, Flowerdew MW: **Transcutaneous electrical nerve stimulation and acupuncture-like transcutaneous electrical nerve stimulation for chronic low back pain.** *Cochrane Database Syst Rev*. 2000; **(2)**: CD000210.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Sator-Katzenschlager SM, Scharbert G, Kozek-Langenecker SA, *et al.*: **The short- and long-term benefit in chronic low back pain through adjuvant electrical versus manual auricular acupuncture.** *Anesth Analg*. 2004; **98**(5): 1359–64, table of contents.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Carlsson CP, Sjölund BH: **Acupuncture for chronic low back pain: a randomized placebo-controlled study with long-term follow-up.** *Clin J Pain*. 2001; **17**(4): 296–305.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Ghoname EA, White PF, Ahmed HE, *et al.*: **Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica.** *Pain*. 1999; **83**(2): 193–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Jauregui JJ, Cherian JJ, Gwam CU, *et al.*: **A Meta-Analysis of Transcutaneous Electrical Nerve Stimulation for Chronic Low Back Pain.** *Surg Technol Int*. 2016; **28**: 296–302.
[PubMed Abstract](#) | [F1000 Recommendation](#)
35. Rajfur J, Pasternok M, Rajfur K, *et al.*: **Efficacy of Selected Electrical Therapies on Chronic Low Back Pain: A Comparative Clinical Pilot Study.** *Med Sci Monit*. 2017; **23**: 85–100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Chan DK, Johnson MI, Sun KO, *et al.*: **Electrical acustimulation of the wrist for chronic neck pain: a randomized, sham-controlled trial using a wrist-ankle acustimulation device.** *Clin J Pain*. 2009; **25**(4): 320–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Gschel B, Kager H, Pipam W, *et al.*: **Analgetische Effizienz von transkutaner elektrischer Nervenstimulation (TENS-Therapie) bei Patienten mit Gonarthrose. Eine prospektive, randomisierte, placebokontrollierte, doppelblinde Studie.** *Schmerz*. 2010; **24**(5): 494–500.
[Publisher Full Text](#)
38. Zeng C, Li H, Yang T, Deng Z, *et al.*: **Electrical stimulation for pain relief in knee osteoarthritis: systematic review and network meta-analysis.** *Osteoarthritis Cartilage*. 2015; **23**(2): 189–202.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Harvey MP, Watier A, Dufort Rouleau É, *et al.*: **Non-invasive stimulation techniques to relieve abdominal/pelvic pain: Is more always better?** *World J Gastroenterol*. 2017; **23**(20): 3758–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Azatcam G, Atalay NS, Akkaya N, *et al.*: **Comparison of effectiveness of Transcutaneous Electrical Nerve Stimulation and Kinesio Taping added to exercises in patients with myofascial pain syndrome.** *J Back Musculoskelet Rehabil*. 2017; **30**(2): 291–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
41. Ferreira AP, Costa DR, Oliveira AI, *et al.*: **Short-term transcutaneous electrical nerve stimulation reduces pain and improves the masticatory muscle activity in temporomandibular disorder patients: a randomized**

- controlled trial. *J Appl Oral Sci.* 2017; **25**(2): 112–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
42. Page MJ, Green S, Mrocek MA, *et al.*: **Electrotherapy modalities for rotator cuff disease.** *Cochrane Database Syst Rev.* 2016; (6): CD012225.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Ramanathan D, Saleh A, Klika AK, *et al.*: **The Use of Transcutaneous Electrical Nerve Stimulation After Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.** *Surg Technol Int.* 2017; **30**: 425–34.
[PubMed Abstract](#)
 44. Salazar AP, Stein C, Marchese RR, *et al.*: **Electric Stimulation for Pain Relief in Patients with Fibromyalgia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.** *Pain Physician.* 2017; **20**(2): 15–25.
[PubMed Abstract](#)
 45. Yokoyama M, Sun X, Oku S, *et al.*: **Comparison of percutaneous electrical nerve stimulation with transcutaneous electrical nerve stimulation for long-term pain relief in patients with chronic low back pain.** *Anesth Analg.* 2004; **98**(6): 1552–6, table of contents.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. **F** Zhang Q, Li YN, Guo YY, *et al.*: **Effects of preconditioning of electroacupuncture on postoperative cognitive dysfunction in elderly: A prospective, randomized, controlled trial.** *Medicine (Baltimore).* 2017; **96**(26): e7375.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 47. Ghoname EA, Craig WF, White PF, *et al.*: **Percutaneous electrical nerve stimulation for low back pain: a randomized crossover study.** *JAMA.* 1999; **281**(9): 818–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. León-Hernández JV, Martín-Pintado-Zugasti A, Frutos LG, *et al.*: **Immediate and short-term effects of the combination of dry needling and percutaneous TENS on post-needling soreness in patients with chronic myofascial neck pain.** *Braz J Phys Ther.* 2016; **20**(5): 422–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. White PF, Li S, Chiu JW: **Electroanalgesia: its role in acute and chronic pain management.** *Anesth Analg.* 2001; **92**(2): 505–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. White PF: **Electroanalgesia: does it have a place in the routine management of acute and chronic pain?** *Anesth Analg.* 2004; **98**(5): 1197–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. **F** Qi L, Tang Y, You Y, *et al.*: **Comparing the Effectiveness of Electroacupuncture with Different Grades of Knee Osteoarthritis: A Prospective Study.** *Cell Physiol Biochem.* 2016; **39**(6): 2331–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 52. Wang SM, Kain ZN, White PF: **Acupuncture analgesia: II. Clinical considerations.** *Anesth Analg.* 2008; **106**(2): 611–21, table of contents.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. **F** Gang J, Mi Y, Wang H: **[Clinical efficacy comparison between electroacupuncture and meloxicam in the treatment of knee osteoarthritis at the early and middle stage: a randomized controlled trial].** *Zhongguo Zhen Jiu.* 2016; **36**(5): 467–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 54. Ding Y, Wang Y, Shi X, *et al.*: **Effect of ultrasound-guided acupotomy vs electroacupuncture on knee osteoarthritis: a randomized controlled study.** *J Tradit Chin Med.* 2016; **36**(4): 450–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Hamblin MR, Demidova TN: **Mechanisms of low level light therapy.** In: Hamblin MR, Wayman RW, Anders J, editors; Saturday 21 January 2006; San Jose CA: SPIE; 2006; 614001.
[Publisher Full Text](#)
 56. Ojea AR, Madi O, Neto RM, *et al.*: **Beneficial Effects of Applying Low-Level Laser Therapy to Surgical Wounds After Bariatric Surgery.** *Photomed Laser Surg.* 2016; **34**(11): 580–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Flemming K, Cullum N: **Systematic reviews of wound care management: Low-level laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy for the treatment of chronic wounds.** *Health Technol Assess.* 2001; **5**: 137–221.
 58. Schneider WL, Hailey D: **Low level laser therapy for wound healing.** Health Technology Assessment. HTA 19. Edmonton, AB: Alberta Heritage Foundation for Medical Research (AHFMR). 1999; 1–23.
[Reference Source](#)
 59. Posten W, Wrone DA, Dover JS, *et al.*: **Low-level laser therapy for wound healing: mechanism and efficacy.** *Dermatol Surg.* 2005; **31**(3): 334–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Sousa RG, Batista Kde N: **Laser therapy in wound healing associated with diabetes mellitus - Review.** *An Bras Dermatol.* 2016; **91**(4): 489–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Ezzat AE, El-Shenawy HM, El-Beghermy MM, *et al.*: **The effectiveness of low-level laser on postoperative pain and edema in secondary palatal operation.** *Int J Pediatr Otorhinolaryngol.* 2016; **89**: 183–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Hawkins D, Abrahamse H: **Phototherapy - a treatment modality for wound healing and pain relief.** *Afr J Biomed Res.* 2007; **10**(2): 99–109.
[Publisher Full Text](#)
 63. Chen YT, Wang HH, Wang TJ, *et al.*: **Early application of low-level laser may reduce the incidence of postherpetic neuralgia (PHN).** *J Am Acad Dermatol.* 2016; **75**(3): 572–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Pol R, Gallesio G, Riso M, *et al.*: **Effects of Superpulsed, Low-Level Laser Therapy on Neurosensory Recovery of the Inferior Alveolar Nerve.** *J Craniofac Surg.* 2016; **27**(5): 1215–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. **F** Pol R, Ruggiero T, Gallesio G, *et al.*: **Efficacy of Anti-Inflammatory and Analgesic of Superpulsed Low Level Laser Therapy After Impacted Mandibular Third Molars Extractions.** *J Craniofac Surg.* 2016; **27**(3): 685–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 66. **F** Eshghpour M, Ahrari F, Takallu M: **Is Low-Level Laser Therapy Effective in the Management of Pain and Swelling After Mandibular Third Molar Surgery?** *J Oral Maxillofac Surg.* 2016; **74**(7): 1322.e1–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 67. **F** Coca KP, Marcacine KO, Gamba MA, *et al.*: **Efficacy of Low-Level Laser Therapy in Relieving Nipple Pain in Breastfeeding Women: A Triple-Blind, Randomized, Controlled Trial.** *Pain Manag Nurs.* 2016; **17**(4): 281–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 68. Macias DM, Coughlin MJ, Zang K, *et al.*: **Low-Level Laser Therapy at 635 nm for Treatment of Chronic Plantar Fasciitis: A Placebo-Controlled, Randomized Study.** *J Foot Ankle Surg.* 2015; **54**(5): 768–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Jastifer JR, Catena F, Doty JF, *et al.*: **Low-Level Laser Therapy for the Treatment of Chronic Plantar Fasciitis: A Prospective Study.** *Foot Ankle Int.* 2014; **35**(6): 566–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. **F** Li Z, Wang Y, Zhang H, *et al.*: **Effectiveness of low-level laser on carpal tunnel syndrome: A meta-analysis of previously reported randomized trials.** *Medicine (Baltimore).* 2016; **95**(31): e4424.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 71. Magri LV, Carvalho VA, Rodrigues FC, *et al.*: **Effectiveness of low-level laser therapy on pain intensity, pressure pain threshold, and SF-MPQ indexes of women with myofascial pain.** *Lasers Med Sci.* 2017; **32**(2): 419–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Fernandes GA, Araújo Júnior RB, Lima AC, *et al.*: **Low-intensity laser (660 NM) has analgesic effects on sternotomy of patients who underwent coronary artery bypass grafts.** *Ann Card Anaesth.* 2017; **20**(1): 52–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. **F** Lima AC, Fernandes GA, Gonzaga IC, *et al.*: **Low-Level Laser and Light-Emitting Diode Therapy for Pain Control in Hyperglycemic and Normoglycemic Patients Who Underwent Coronary Bypass Surgery with Internal Mammary Artery Grafts: A Randomized, Double-Blind Study with Follow-Up.** *Photomed Laser Surg.* 2016; **34**(6): 244–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 74. Fallah A, Mirzaei A, Gutknecht N, *et al.*: **Clinical effectiveness of low-level laser treatment on peripheral somatosensory neuropathy.** *Lasers Med Sci.* 2017; **32**(3): 721–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. de Andrade AL, Bossini PS, Parizotto NA: **Use of low level laser therapy to control neuropathic pain: A systematic review.** *J Photochem Photobiol B.* 2016; **164**: 36–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Basford JR, Malanga GA, Krause DA, *et al.*: **A randomized controlled evaluation of low-intensity laser therapy: plantar fasciitis.** *Arch Phys Med Rehabil.* 1998; **79**(3): 249–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Gür A, Karakoc M, Nas K, *et al.*: **Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial.** *Rheumatol Int.* 2002; **22**(5): 188–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Gür A, Karakoç M, Nas K, *et al.*: **Efficacy of low power laser therapy in fibromyalgia: a single-blind, placebo-controlled trial.** *Lasers Med Sci.* 2002; **17**(1): 57–61.
[PubMed Abstract](#)
 79. Vayvay ES, Tok D, Turgut E, *et al.*: **The effect of Laser and taping on pain, functional status and quality of life in patients with fibromyalgia syndrome: A placebo-randomized controlled clinical trial.** *J Back Musculoskeletal Rehabil.* 2016; **29**(1): 77–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. **F** Eslamipour F, Motamedian SR, Bagheri F: **Ibuprofen and Low-level Laser Therapy for Pain Control during Fixed Orthodontic Therapy: A Systematic Review of Randomized Controlled Trials and Meta-analysis.** *J Contemp Dent Pract.* 2017; **18**(6): 527–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 81. Alan H, Yolcu Ü, Koparal M, *et al.*: **Evaluation of the effects of the low-level laser therapy on swelling, pain, and trismus after removal of impacted lower third molar.** *Head Face Med.* 2016; **12**(1): 25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 82. **F** Santinoni CD, Oliveira HF, Batista VE, *et al.*: **Influence of low-level laser**

- therapy on the healing of human bone maxillofacial defects: A systematic review. *J Photochem Photobiol B*. 2017; 169: 83–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
83. Chen J, Huang Z, Ge M, *et al.*: Efficacy of low-level laser therapy in the treatment of TMDs: a meta-analysis of 14 randomised controlled trials. *J Oral Rehabil*. 2015; 42(4): 291–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. Javed F, Kellesarian SV, Romanos GE: Role of diode lasers in oro-facial pain management. *J Biol Regul Homeost Agents*. 2017; 31(1): 153–5.
[PubMed Abstract](#)
 85. Lima AG, Antequera R, Peres MP, *et al.*: Efficacy of low-level laser therapy and aluminum hydroxide in patients with chemotherapy and radiotherapy-induced oral mucositis. *Braz Dent J*. 2010; 21(3): 186–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Gouvêa de Lima A, Villar RC, de Castro G Jr, *et al.*: Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. *Int J Radiat Oncol Biol Phys*. 2012; 82(1): 270–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 87. Oton-Leite AF, Elias LS, Morais MO, *et al.*: Effect of low level laser therapy in the reduction of oral complications in patients with cancer of the head and neck submitted to radiotherapy. *Spec Care Dentist*. 2013; 33(6): 294–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Gautam AP, Fernandes DJ, Vidyasagar MS, *et al.*: Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy—a randomized controlled trial. *Support Care Cancer*. 2013; 21(5): 1421–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 89. Amadori F, Bardellini E, Conti G, *et al.*: Low-level laser therapy for treatment of chemotherapy-induced oral mucositis in childhood: a randomized double-blind controlled study. *Lasers Med Sci*. 2016; 31(6): 1231–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 90. Zanin T, Zanin F, Carvalhosa AA, *et al.*: Use of 660-nm diode laser in the prevention and treatment of human oral mucositis induced by radiotherapy and chemotherapy. *Photomed Laser Surg*. 2010; 28(2): 233–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 91. Storz MA, Gronwald B, Gottschling S, *et al.*: Photobiomodulation therapy in breast cancer-related lymphedema: a randomized placebo-controlled trial. *Photodermatol Photoimmunol Photomed*. 2017; 33(1): 32–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. Ebid AA, El-Sodany AM: Long-term effect of pulsed high-intensity laser therapy in the treatment of post-mastectomy pain syndrome: a double blind, placebo-control, randomized study. *Lasers Med Sci*. 2015; 30(6): 1747–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. Robijns J, Censabella S, Bulens P, *et al.*: The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature. *Lasers Med Sci*. 2017; 32(1): 229–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 94. Berns MW, Nelson JS: Laser Applications in Biomedicine. Part I: Biophysics, Cell Biology, and Biostimulation. *J Laser Appl*. 1988; 1: 34–9.
[Publisher Full Text](#)
 95. McGuff PE, Deterling RA Jr, Gottlieb LS: Tumorcidal effect of laser energy on experimental and human malignant tumors. *N Engl J Med*. 1965; 273(9): 490–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 96. McGuff PE, Deterling RA Jr, Gottlieb LS: Laser radiation for metastatic malignant melanoma. *JAMA*. 1966; 195(5): 393–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 97. McGuff PE, Gottlieb LS, Katayama I, *et al.*: Comparative study of effects of laser and/or ionizing radiation therapy on experimental or human malignant tumors. *Am J Roentgenol Radium Ther Nucl Med*. 1966; 96(3): 744–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 98. de C Monteiro JS, Pinheiro AN, de Oliveira SC, *et al.*: Influence of laser phototherapy (λ660 nm) on the outcome of oral chemical carcinogenesis on the hamster cheek pouch model: histological study. *Photomed Laser Surg*. 2011; 29(11): 741–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 99. Gavish L, Asher Y, Becker Y, *et al.*: Low level laser irradiation stimulates mitochondrial membrane potential and disperses subnuclear promyelocytic leukemia protein. *Lasers Surg Med*. 2004; 35(5): 369–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 100. Karu T: Primary and secondary mechanisms of action of visible to near-IR radiation on cells. *J Photochem Photobiol B*. 1999; 49(1): 1–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
 101. Sperandio FF, Giudice FS, Corrêa L, *et al.*: Low-level laser therapy can produce increased aggressiveness of dysplastic and oral cancer cell lines by modulation of Akt/mTOR signaling pathway. *J Biophotonics*. 2013; 6(10): 839–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 102. Rhee YH, Moon JH, Choi SH, *et al.*: Low-Level Laser Therapy Promoted Aggressive Proliferation and Angiogenesis Through Decreasing of Transforming Growth Factor-β1 and Increasing of Akt/Hypoxia Inducible Factor-1α in Anaplastic Thyroid Cancer. *Photomed Laser Surg*. 2016; 34(6): 229–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 103. Basford JR, Sheffield CG, Harmsen WS: Laser therapy: a randomized, controlled trial of the effects of low-intensity Nd:YAG laser irradiation on musculoskeletal back pain. *Arch Phys Med Rehabil*. 1999; 80(6): 647–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 104. Glazov G, Yelland M, Emery J: Low-level laser therapy for chronic non-specific low back pain: a meta-analysis of randomised controlled trials. *Acupunct Med*. 2016; 34(5): 328–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 105. Boyraz I, Yildiz A, Koc B, *et al.*: Comparison of high-intensity laser therapy and ultrasound treatment in the patients with lumbar discopathy. *Biomed Res Int*. 2015; 2015: 304328.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 106. Chen L, Liu D, Zou L, *et al.*: Efficacy of high intensity laser therapy in treatment of patients with lumbar disc protrusion: A randomized controlled trial. *J Back Musculoskelet Rehabil*. 2017.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 107. Choi HW, Lee J, Lee S, *et al.*: Effects of high intensity laser therapy on pain and function of patients with chronic back pain. *J Phys Ther Sci*. 2017; 29(6): 1079–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 108. Pekyavas NO, Baltaci G: Short-term effects of high-intensity laser therapy, manual therapy, and Kinesio taping in patients with subacromial impingement syndrome. *Lasers Med Sci*. 2016; 31(6): 1133–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 109. Kadhim-Saleh A, Maganti H, Ghert M, *et al.*: Is low-level laser therapy in relieving neck pain effective? Systematic review and meta-analysis. *Rheumatol Int*. 2013; 33(10): 2493–501.
[PubMed Abstract](#) | [Publisher Full Text](#)
 110. Alayat MS, Atya AM, Ali MM, *et al.*: Long-term effect of high-intensity laser therapy in the treatment of patients with chronic low back pain: a randomized blinded placebo-controlled trial. *Lasers Med Sci*. 2014; 29(3): 1065–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 111. Alayat MS, Mohamed AA, Helal OF, *et al.*: Efficacy of high-intensity laser therapy in the treatment of chronic neck pain: a randomized double-blind placebo-control trial. *Lasers Med Sci*. 2016; 31(4): 687–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 112. Chow RT, Johnson MI, Lopes-Martins RA, *et al.*: Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. *Lancet*. 2009; 374(9705): 1897–908.
[PubMed Abstract](#) | [Publisher Full Text](#)
 113. Haladaj R, Pingot M, Topol M: The Effectiveness of Cervical Spondylosis Therapy with Saunders Traction Device and High-Intensity Laser Therapy: A Randomized Controlled Trial. *Med Sci Monit*. 2017; 23: 335–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 114. Dundar U, Turkmen U, Toktas H, *et al.*: Effect of high-intensity laser therapy in the management of myofascial pain syndrome of the trapezius: a double-blind, placebo-controlled study. *Lasers Med Sci*. 2015; 30(1): 325–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 115. Kim GJ, Choi J, Lee S, *et al.*: The effects of high intensity laser therapy on pain and function in patients with knee osteoarthritis. *J Phys Ther Sci*. 2016; 28(11): 3197–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 116. Angelova A, Ilieva EM: Effectiveness of High Intensity Laser Therapy for Reduction of Pain in Knee Osteoarthritis. *Pain Res Manag*. 2016; 2016: 9163618.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 117. Alayat MSM, Abdel-Kafy EM, Elsoudany AM, *et al.*: Efficacy of high intensity laser therapy in the treatment of male with osteopenia or osteoporosis: a randomized placebo-controlled trial. *J Phys Ther Sci*. 2017; 29(9): 1675–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 118. Kheshie AR, Alayat MS, Ali MM: High-intensity versus low-level laser therapy in the treatment of patients with knee osteoarthritis: a randomized controlled trial. *Lasers Med Sci*. 2014; 29(4): 1371–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 119. Kul'chitskaya DB, Konchugova TV, Luk'yanova TV, *et al.*: [The substantiation for the application of high-intensity laser therapy for the treatment of the patients presenting with gonarthrosis]. *Vopr Kurortol Fizioter Lech Fiz Kult*. 2015; 92(1): 23–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 120. Alayat MS, Elsodany AM, El Fiky AA: Efficacy of high and low level laser therapy in the treatment of Bell's palsy: a randomized double blind placebo-controlled trial. *Lasers Med Sci*. 2014; 29(1): 335–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 121. Karaca B: Effectiveness of High-Intensity Laser Therapy in Subacromial Impingement Syndrome. *Photomed Laser Surg*. 2016; 34(6): 223–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 122. Kim SH, Kim YH, Lee HR, *et al.*: Short-term effects of high-intensity laser therapy on frozen shoulder: A prospective randomized control study. *Man*

- Ther. 2015; **20**(6): 751–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
123. Akkurt E, Kucuksen S, Yılmaz H, *et al.*: Long term effects of high intensity laser therapy in lateral epicondylitis patients. *Lasers Med Sci.* 2016; **31**(2): 249–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 124. Casale R, Damiani C, Maestri R, *et al.*: Pain and electrophysiological parameters are improved by combined 830-1064 high-intensity LASER in symptomatic carpal tunnel syndrome versus Transcutaneous Electrical Nerve Stimulation. A randomized controlled study. *Eur J Phys Rehabil Med.* 2013; **49**(2): 205–11.
[PubMed Abstract](#)
 125. **F** Gottschling S, Meyer S, Gribova I, *et al.*: Laser acupuncture in children with headache: a double-blind, randomized, bicenter, placebo-controlled trial. *Pain.* 2008; **137**(2): 405–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 126. Tomaz de Magalhães M, Núñez SC, Kato IT, *et al.*: Light therapy modulates serotonin levels and blood flow in women with headache. A preliminary study. *Exp Biol Med (Maywood).* 2016; **241**(1): 40–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 127. Costantini D, Delogu G, Lo Bosco L, *et al.*: The treatment of cranio-facial pain by electroacupuncture and laser irradiation. *Ann Ital Chir.* 1997; **68**(4): 505–9.
[PubMed Abstract](#)
 128. Nakamura T, Ebihara S, Ohkuni I, *et al.*: Low Level Laser Therapy for chronic knee joint pain patients. *Laser Ther.* 2014; **23**(4): 273–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 129. Youssef EF, Muaidi QI, Shanb AA: Effect of Laser Therapy on Chronic Osteoarthritis of the Knee in Older Subjects. *J Lasers Med Sci.* 2016; **7**(2): 112–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 130. Viliani T, Carrabba C, Mangone G: High intensity pulsed Nd:YAG laser in painful knee osteoarthritis: the biostimulatin protocol. *Energy for Health.* 2012; **9**: 18–22.
[Reference Source](#)
 131. Ip D: Does addition of low-level laser therapy (LLLT) in conservative care of knee arthritis successfully postpone the need for joint replacement? *Lasers Med Sci.* 2015; **30**(9): 2335–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 132. Iijima K, Shimoyama N, Shimoyama M, *et al.*: Evaluation of analgesic effect of low-power He:Ne laser on postherpetic neuralgia using VAS and modified McGill pain questionnaire. *J Clin Laser Med Surg.* 1991; **9**(2): 121–6.
[PubMed Abstract](#)
 133. Iijima K, Shimoyama N, Shimoyama M, *et al.*: Effect of repeated irradiation of low-power He-Ne laser in pain relief from postherpetic neuralgia. *Clin J Pain.* 1989; **5**(3): 271–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 134. Zverev VV, Makarov OV, Khashukoeva AZ, *et al.*: *In vitro* studies of the antihypertensive effect of photodynamic therapy. *Lasers Med Sci.* 2016; **31**(5): 849–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 135. Vernon LF: Low-level laser for trigeminal neuralgia. *Practica Pain Management.* 2008; 56–63.
[Reference Source](#)
 136. Falaki F, Nejat AH, Dalirsani Z: The Effect of Low-level Laser Therapy on Trigeminal Neuralgia: A Review of Literature. *J Dent Res Dent Clin Dent Prospects.* 2014; **8**(1): 1–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 137. White PF, Zafereo J, Elvir-Lazo OL, *et al.*: Treatment of drug-resistant fibromyalgia symptoms using high-intensity laser therapy: a case-based review. *Rheumatol Int.* 2017; 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 138. Huang YY, Chen AC, Carroll JD, *et al.*: Biphasic dose response in low level light therapy. *Dose Response.* 2009; **7**(4): 358–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 139. Moore KC, Hira N, Cruikshank JA: The effect of infra-red diode laser irradiation on the duration and severity of postoperative pain: A double-blind trial. *Laser Ther.* 1992; **4**(4): 145–9.
[Publisher Full Text](#)
 140. Panton L, Simonavice E, Williams K, *et al.*: Effects of Class IV laser therapy on fibromyalgia impact and function in women with fibromyalgia. *J Altern Complement Med.* 2013; **19**(5): 445–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 141. White PF, Elvir-Lazo OL, Hernandez H: A novel treatment for chronic opioid use after surgery. *J Clin Anesth.* 2017; **40**: 51–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 142. White PF, Cao X, Elvir Lazo L, *et al.*: Effect of High-Intensity Laser Treatments on Chronic Pain Related to Osteoarthritis in Former Professional Athletes: A Case Series. *J Mol Biomark Diagn.* 2017; **8**: 343.
[Publisher Full Text](#)
 143. Leal-Junior EC, Vanin AA, Miranda EF, *et al.*: Effect of phototherapy (low-level laser therapy and light-emitting diode therapy) on exercise performance and markers of exercise recovery: a systematic review with meta-analysis. *Lasers Med Sci.* 2015; **30**(2): 925–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
 144. de Oliveira AR, Vanin AA, Tomazoni SS, *et al.*: Pre-Exercise Infrared Photobiomodulation Therapy (810nm) in Skeletal Muscle Performance and Postexercise Recovery in Humans: What Is the Optimal Power Output? *Photomed Laser Surg.* 2017; **35**(11): 595–603.
[PubMed Abstract](#) | [Publisher Full Text](#)
 145. Foley J, Vasily DB, Bradle J, *et al.*: 830 nm light-emitting diode (led) phototherapy significantly reduced return-to-play in injured university athletes: a pilot study. *Laser Ther.* 2016; **25**(1): 35–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 146. Bordvik DH, Haslerud S, Naterstad IF, *et al.*: Penetration Time Profiles for Two Class 3B Lasers in *In Situ* Human Achilles at Rest and Stretched. *Photomed Laser Surg.* 2017; **35**(10): 546–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 147. Leal-Junior EC, Johnson DS, Saltmarche A, *et al.*: Adjunctive use of combination of super-pulsed laser and light-emitting diodes phototherapy on nonspecific knee pain: double-blinded randomized placebo-controlled trial. *Lasers Med Sci.* 2014; **29**(6): 1839–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 148. De Marchi T, Schmitt VM, Danúbia da Silva Fabro C, *et al.*: Phototherapy for Improvement of Performance and Exercise Recovery: Comparison of 3 Commercially Available Devices. *J Athl Train.* 2017; **52**(5): 429–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 149. **F** Notarnicola A, Maccagnano G, Tafuri S, *et al.*: High level laser therapy for the treatment of lower back pain: clinical efficacy and comparison of different wavelengths. *J Biol Regul Homeost Agents.* 2016; **30**(4): 1157–64.
[PubMed Abstract](#) | [F1000 Recommendation](#)
 150. Murthy VH: Ending the Opioid Epidemic - A Call to Action. *N Engl J Med.* 2016; **375**(25): 2413–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 151. Rudd RA, Aleshire N, Zibbell JE, *et al.*: Increases in Drug and Opioid Overdose Deaths—United States, 2000–2014. *MMWR Morb Mortal Wkly Rep.* 2016; **64**(50–51): 1378–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 152. Compton WM, Jones CM, Baldwin GT: Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. *N Engl J Med.* 2016; **374**(2): 154–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 153. Califf RM, Woodcock J, Ostroff S: A Proactive Response to Prescription Opioid Abuse. *N Engl J Med.* 2016; **374**(15): 1480–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 154. **F** Qaseem A, Wilt TJ, McLean RM, *et al.*: Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med.* 2017; **166**(7): 514–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 155. Dowell D, Haegerich TM, Chou R: CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. *JAMA.* 2016; **315**(15): 1624–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 156. **F** Barnett ML, Olenski AR, Jena AB: Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use. *N Engl J Med.* 2017; **376**(7): 663–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 157. White PF: It is time to consider non-pharmacologic alternatives to opioid analgesics for treating chronic pain. *J Mol Biomark Diagn.* 2017; **8**: 341–2.
[Publisher Full Text](#)
 158. Wang SM, Kain ZN, White P: Acupuncture analgesia: I. The scientific basis. *Anesth Analg.* 2008; **106**(2): 602–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
 159. Chow R, Armati P, Laakso EL, *et al.*: Inhibitory effects of laser irradiation on peripheral mammalian nerves and relevance to analgesic effects: a systematic review. *Photomed Laser Surg.* 2011; **29**(6): 365–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 160. Chow RT, Armati PJ: Photobiomodulation: Implications for Anesthesia and Pain Relief. *Photomed Laser Surg.* 2016; **34**(12): 599–609.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Stephan A. Schug**

Anaesthesiology, Pharmacology and Anaesthesiology Unit, University of Western Australia, Perth, WA, Australia

Competing Interests: No competing interests were disclosed.

2. **Charles Argoff**

Department of Neurology, Albany Medical Center, Albany, NY, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research